A comparative study of laboratory findings in PCR-positive and PCR-negative COVID-19 hospitalized patients

Hassan Abolghasemi1 · Davood Bashash2 · Ramezan Jafari3 · Parisa Naseri4 · Mahdieh Farzanehpour5 · Masomeh Bolandian5 · Majededin Ghalavand3 · Mohammad Mahdi Pourhaji Chaghush6 · Hossein Aghamollaei7 · Hamid Sedighian1 · Abbas Ali Imani Fooladi1

Received: 5 April 2021 / Accepted: 8 September 2021 / Published online: 15 September 2021
© Royal Academy of Medicine in Ireland 2021

Abstract

Introduction Given the many misconceptions in terms of both diagnosis and treatment, SARS-CoV-2 continues to infect and victimize. Notwithstanding molecular testing is the gold standard method of in vitro diagnostic, the often long-waiting time, as well as false-negative results are daunting challenges facing us. In this study, we aimed to report the diagnostic value of laboratory findings in COVID-19 patients, with an extensive focus on the differences between PCR-positive and PCR-negative cases.

Patients and methods We did a retrospective single-centre study on a large cohort of 1546 COVID-19 patients in Tehran, Iran. Based on clinical symptoms, chest CTs were performed for all the patients. Also, molecular testing of swab specimens was also performed for 1450 cases.

Results All the data on laboratory results were retrospectively extracted from medical records. Of the 1546 patients, 1040 (67.5%) were male and 506 (32.5%) were female with the mean age of 55.67. On admission, 31.4% of the whole study population displayed lymphopenia and 38.9% showed neutrophilia. Decreased hemoglobin and mild thrombocytopenia were also found in 40% and 18.6% of cases, respectively. Elevated lactate dehydrogenase in nearly 75% of COVID-19 cases was the most common alteration amongst biochemical parameters which together with increased ESR and CRP could serve as diagnostic markers in SARS-CoV-2 infection. Of the 1450 patients with a PCR result, 439 (28.3%) were PCR-negative and 1011 (65.3%) were PCR-positive. Notably, lymphopenia and increased AST were higher in the PCR-positive group than their negative counterparts. Albeit being in the normal range, a significant decrease in the number of monocytes was also evident in the PCR-positive cases.

Conclusions As far we are aware, this is the first time that we reported a comprehensive exploration of laboratory characteristics of a large cohort of hospitalized COVID-19 patients from Iran, hoping that these data will cast more light on the diagnostic significance of these parameters.

Keywords COVID-19 · Diagnosis · Iran · Laboratory · PCR · Polymerase chain reaction · SARS-CoV-2

Hassan Abolghasemi and Davood Bashash contributed equally to this manuscript as the first author.

© Abbas Ali Imani Fooladi
imanifouladi.a@gmail.com

1 Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Radiology, Baqiyatallah University of Medical Sciences, Tehran, Iran
4 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
6 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
7 Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
Introduction

Undoubtedly, the end of 2019 will be recorded as one of the most sinister times in the history of medicine, when an outbreak of fatal pneumonia caused by a novel coronavirus (later designated as SARS-CoV-2 [1, 2]) hits the headlines. In fact, the original heartfelt belief of the world that the disease—reported from Wuhan [3, 4]—is nothing more than a common cold was disappeared in the blink of an eye when the World Health Organization (WHO) issued a public health emergency on 30 January 2020 [3], followed by the declaration of a viral pandemic on 11 March [5]. Although the containment measures executed in the virus-originating country have, at least for the meantime, decreased the risk of contagion profoundly; needless to say, it is not the case in most countries of the world, including the USA, Spain, Italy, France, the UK, and Iran. Even though the general belief—by matching the number of deaths to the total number of infected cases—is that most patients with coronavirus disease 2019 (abbreviated to COVID-19) are recovering, stealing a glance at the outrageous statistics of deaths increasing day after day recaps that SARS-CoV-2 still is taking toll [6]. In Iran, where the virus was transmitted probably by a merchant who had traveled to China (Fig. 1), infection of over 1,000,000 people with more than 51,000 deaths ranked this country as the 15th highest number of SARS-CoV-2 cases as of 13 December 2020 (https://www.worldometers.info/coronavirus/country/iran).

Timely identification of COVID-19 carriers is critical not only to mitigate viral spread but also to alleviate disease progression in a well-controlled manner. Notwithstanding the fact that the nucleic acid test serves as the gold standard method for the etiological detection of SARS-CoV-2 infection, the existence of the false-negative results is the main challenge [7, 8]. Also, variable distribution of virus across the respiratory tract between patients, missing patients who have recovered from the disease, and the prerequisite of certified laboratories, expensive equipment and skilled personnel denote other limitations to PCR-based diagnostic methods [9]. Recitation of this concern from the fact that such limitations are even more highlighted in countries with restricted assets further uncovers the urgent necessity for alternative tests to timely detect COVID-19 patients. In this study, we aimed to report a comprehensive exploration of laboratory characteristics of a large cohort of 1546 hospitalized patients with COVID-19 of Baqiyatallah Hospital of Tehran, Iran, from February 30 to April 10, 2020, with an extensive focus on the differences between PCR-positive and PCR-negative cases.

Patients and methods

Participants

This retrospective single-center study, conducted on a large cohort of 1546 COVID-19 patients recruited at Baqiyatallah Hospital in Tehran, Iran, from February 30 to April 10, 2020, was approved by Baqiyatallah Hospital Ethics Committee, and written informed consent was waived from patients. Based on clinical symptoms including cough, sputum, fever, dyspnea, and pleuritic chest pain as well as coarse crackles on auscultation, chest CT was requested for all the patients admitted to the hospital. All the cases with a positive chest CT were defined as COVID-19 patients and entered into this study.

Procedures

All imaging features including pure ground-glass opacity (GGO), pure consolidation, mixed GGO and consolidation, reversed halo, interalvesional traction bronchiectasis, crazy-paving, interalvesional vascular enlargement, linear opacities, lymph node enlargement, pleural effusion, and pericardial effusion were reviewed and evaluated by an expert radiologist. In detail, a thin-section CT involvement score was assigned on the basis of all abnormal areas involved. Each lobe was assigned a score that was based on the following: score 0, 0% involvement; score 1, less than
5% involvement; score 2, 5 to 25% involvement; score 3, 26 to 49% involvement; score 4, 50 to 75% involvement; and score 5, greater than 75% involvement. There was a score of 0 to 5 for each lobe, with a total possible score of 0 to 25. Next, a total pulmonary infiltration score was calculated; that is to say, the sum of scores of all the five pulmonary lobes was used. The number of affected lung lobes was also counted. The location of the lesion was considered as peripheral if it was in the outer one-third of the lung; otherwise, it was considered as central. Other radiological patterns were also evaluated.

In addition, throat swab specimens from the upper respiratory tract were obtained and maintained in the virus-transport medium. The presence of SARS-CoV-2 in pharyngeal swab specimens was detected by RT-PCR analysis for 1450 cases (of 1546 cases, 96 patients did not have a PCR test). The sequences of the primers targeting envelope gene of CoV were as follows: forward primer 5′-ACTTCTTTTCTTGTTTGCAGTG-3′; reverse primer 5′-GCAGACATACGCACCACAACT-3′. Conditions for the amplifications were 50 °C for 15 min, 95 °C for 3 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 30 s. All the data on laboratory results were retrospectively extracted from patients’ electronic medical records. Values of the hematological parameters (WBC-, RBC-, and Plt-related indices), inflammation-related factors (ESR and CRP), biochemical parameters (Cr, BUN, CPK, LDH, AST, ALT, Na+, K+), and blood gas analysis (pH, PO2, PCO2, O2 saturation, HCO3−, and lactate) of COVID-19 patients were analyzed and related to their corresponding RT-PCR.

### Statistical analysis

The continuous variables were examined to determine the normality of the distribution using histograms, measures of skewness and kurtosis, and Kolmogorov–Smirnov test. The normally distributed variables were described as the means ± standard deviation (SD), and the skewed distributed variables were expressed as the median and interquartile range (25–75%). Categorical variables were summarized as frequencies (percentages). The normally distributed continuous variables were compared between positive and negative PCR groups using the two independent sample *t*-test and non-normally distributed variables with the Mann–Whitney *U* test. Comparisons of categorical variables between groups were conducted using the chi-square test of independence. All tests were two-sided, and a *P* value of less than 0.05 was considered to indicate a statistically significant difference. All the statistical analyses were performed using the IBM SPSS version 24.0 (IBM Corp., Armonk, NY, USA).

### Results

#### The main characteristics of the patients

Out of 1546 COVID-19 patients (based on the results of a positive chest CT), 1040 (67.5%) were male and 506 (32.5%) were female. The mean age was 55.67 (±14.22). While 29% of the patients were between 50 and 59 years, cases under the age of 40 were the least studied population with an approximate estimate of 15%. After removing 96 patients who did not have a PCR test, we sub-grouped patients to PCR-negative (*N* = 439; 28.3%) and PCR-positive (*N* = 1011; 65.3%) cases. We found almost the same trend in the percentage of males and females between these two groups (34.4% vs 31.7% female in PCR-negative and -positive cases, respectively). The age distribution pattern was also the same, just noting that the percentage of patients in the age range of 60–70 years was slightly higher in the PCR-positive group (24.1% vs 19.8%). A list of requested tests along with the number of each of these tests performed in different groups is summarized in Table 1.

#### Hematologic findings in COVID-19 patients

The complete blood count (CBC) test was performed nearly for all the patients (99.4%), and the results were presented in Table 2. Although we found that WBC counts of approximately 94% of patients were within the normal range, 31.4% of the whole study population displayed lymphopenia (lymphocyte count < 1.1 × 109/L). Increased number of neutrophils (> 6.3 × 109/L), on the other hand, was also observed in 38.9% of cases, highlighting the fact that lymphopenia along with neutrophilia may seemingly be appropriate items that should be taken into account in COVID-19 diagnosis. Decreased levels of hemoglobin (Hb) and mild thrombocytopenia—which were present in 40% and 18.6% of cases, respectively—may also contribute to the diagnosis of the disease. With respect to the information of CBC tests relevant to PCR results, we found that the percentage of COVID-19 cases with lymphopenia was higher in the PCR-positive group than their negative counterparts (33.1% vs 28.5%; *P* = 0.08). Even though being in the normal range, a significant decrease in the number of monocytes was also evident in the PCR-positive cases (*P* = 0.005). While values of RBC, hemoglobin (Hb), hematocrit (Hct), and MCHC were lower in cases with negative PCR results, there was no significant difference relevant to platelet-related parameters between these groups (Table 2).

#### Biochemical and blood gas findings in COVID-19 patients

As expected, 82% and 87% of the whole study population showed elevated ESR and CRP values, respectively;
suggesting that CRP may provide more valuable information than ESR (Table 3). Nonetheless, knowing that increased values of these parameters could serve as non-specific factors alarming the wide range of inflammatory conditions may reduce the diagnostic value of these parameters to some extent. Analysis of biochemical parameters also revealed an increased level of creatinine and BUN in 47% and 28% of COVID-19 cases, respectively. Elevated AST and ALT (nearly in 33% of all patients) also mirror an unfavorable clinical picture of the disease related to virus-mediated liver injury. Of particular importance, the change in biochemical parameters was not limited only to these factors, as an increase in CPK and especially in LDH values was eye-catching in the disease. As represented in Table 3, elevated LDH in nearly 75% of COVID-19 cases was the most common alteration amongst biochemical parameters which together with increased ESR and CRP could serve as invaluable diagnostic markers in SARS-CoV-2 infection. Albeit AST level was significantly higher in PCR-positive cases compared to those with negative results, alterations of other factors were within a close range and actually represented no significant change between these two groups. Change in pH was observed in 18% of the patients, of which 7.8% experienced acidosis and the remaining displayed alkalosis. Decreased PO₂ and O₂ saturation were also reported in 23% of the whole study population (Table 3). However, since only 418 out of 1546 cases (27%) had the ABG test, it should be considered as a limitation to interpreting the results of the ABG test.

**Discussion**

In this retrospective single-center study which reflects laboratory findings of a large cohort of 1546 COVID-19 patients from Tehran, Iran, 439 cases (28.3%) had negative
Table 2  Values of hematological parameters in COVID-19 patients

| WBC-related            | Normal ranges                          | All Patients (N = 1546) | PCR Negative (N = 439) | PCR Positive (N = 1011) | P Value |
|------------------------|----------------------------------------|-------------------------|------------------------|-------------------------|---------|
| **WBC count**          | 3.5–11 (×10^9/L)                       | 7.33 (5.70–8.90)        | 7.6 (5.7–9.1)          | 7.3 (5.7–8.85)          | 0.118   |
| < 3.5                   | 2.3%                                   | 1.6%                    | 2.6%                   |                         |         |
| 3.5–11                  | 93.7%                                  | 92.9%                   | 94.4%                  |                         |         |
| > 11                   | 3.3%                                   | 5.5%                    | 2.5%                   |                         |         |
| **Lymphocyte count**   | 1.1–3.2 (×10^9/L)                      | 1.58 (0.91–2.26)        | 1.77 (0.98–2.45)       | 1.53 (0.89–2.21)        | 0.004   |
| < 1.1                  | 31.4%                                  | 28.5%                   | 33.1%                  |                         | 0.08    |
| **Neutrophil count**   | 1.8–6.3 (×10^9/L)                      | 5.68 (4.12–7.29)        | 5.81 (4.23–7.22)       | 5.68 (4.13–7.42)        | 0.691   |
| < 1.8                  | 0.7%                                   | 0.2%                    | 0.9%                   |                         |         |
| > 6.3                  | 38.9%                                  | 41%                     | 39.4%                  |                         |         |
| **Monocyte count**     | 0.1–0.7 (×10^9/L)                      | 0.49 (0.36–0.65)        | 0.53 (0.39–0.67)       | 0.47 (0.36–0.63)        | 0.005   |
| **Eosinophil count**   | 0.06–0.46 (×10^9/L)                    | 0.09 (0.03–0.21)        | 0.09 (0.04–0.23)       | 0.09 (0.03–0.20)        | 0.164   |
| **Basophil count**     | 0.01–0.3 (×10^9/L)                     | 0.04 (0.03–0.07)        | 0.04 (0.03–0.08)       | 0.05 (0.03–0.07)        | 0.711   |
| **RBC count**          | Female: 3.7–5.2 (×10^12/L)             | 4.94 (±0.63)            | 4.83 (±0.61)           | 4.99 (±0.64)            | 0.000   |
|                       | Male: 4–5.7 (×10^12/L)                 |                         |                        |                        |         |
| < 36 (Female)          | 8.7%                                   | 13.7%                   | 6.4%                   |                         | 0.000   |
| < 39 (Male)            | 22.6%                                  | 26.2%                   | 19.9%                  |                         | 0.007   |
| **Hemoglobin**         | Female: 12–15.5 g/dL                   | 14.40 (13.10–15.60)     | 14.2 (12.82–15.3)      | 14.5 (13.3–15.7)        | 0.005   |
|                       | Male: 13–17.5 g/dL                     |                         |                        |                        |         |
| < 12 (Female)          | 14.7%                                  | 18.5%                   | 13.1%                  |                         | 0.008   |
| < 13 (Male)            | 24.3%                                  | 27.3%                   | 22.3%                  |                         | 0.037   |
| **Hematocrit**         | Female: 36–46%                         | 42.17 (±4.82)           | 41.45 (±4.95)          | 42.59 (±4.74)           | 0.000   |
|                       | Male: 39–51%                           |                         |                        |                        |         |
| < 36 (Female)          | 8.7%                                   | 13.7%                   | 6.4%                   |                         | 0.000   |
| < 39 (Male)            | 22.6%                                  | 26.2%                   | 19.9%                  |                         | 0.007   |
| **MCV**                | 81–96 FL                               | 87.72 (84.55–90.93)     | 87.79 (84.74–90.83)    | 87.78 (84.66–91.05)     | 0.936   |
| < 81                   | 10%                                    | 8.4%                    | 9.9%                   |                         | 0.509   |
| > 96                   | 4.5%                                   | 4.1%                    | 4.9%                   |                         |         |
| **MCH**                | 27–33 pg                               | 30.14 (28.76–31.23)     | 30.18 (28.77–31.18)    | 30.19 (28.81–31.3)      | 0.462   |
| < 27                   | 9.6%                                   | 8.9%                    | 9.2%                   |                         | 0.848   |
| **MCHC**               | 32–36 g/dL                             | 34.70 (33.97–35.51)     | 34.63 (33.87–35.43)    | 34.81 (34.08–35.57)     | 0.013   |
| < 32                   | 3.4%                                   | 3.6%                    | 2.9%                   |                         | 0.434   |
| **RDW-CV**             | 11–14%                                 | 13.4 (12.7–14.3)        | 13.3 (12.7–14.3)       | 13.4 (12.8–14.4)        | 0.117   |
| > 14                   | 32.5%                                  | 29.8%                   | 34.1%                  |                         | 0.11    |
| **RDW-SD**             | 35–56 FL                               | 43.95 (41.37–46.70)     | 43.9 (41.6–45.9)       | 44.1 (41.4–47)          | 0.263   |
| > 56                   | 1.9%                                   | 1.6%                    | 2.1%                   |                         | 0.539   |
| **Plt-related**        | 150–400 (×10^9/L)                      | 238 (168–325)           | 245 (172–339.75)       | 237 (166.5–325)         | 0.202   |
| < 150                  | 18.6%                                  | 16.6%                   | 19.6%                  |                         | 0.185   |
| **PDW**                | 12–20%                                 | 16.2 (15.7–16.6)        | 16.1 (15.6–16.6)       | 16.2 (15.8–16.6)        | 0.112   |
| **MPV**                | 8.0–12.7 FL                            | 9.7 (9.3–9.9)           | 9.7 (9.2–9.9)          | 9.7 (9.3–9.9)           | 0.994   |
| **P-LCR**              | 11.9–66.9                              | 31.18 (±4.88)           | 30.04 (±8.36)          | 31.56 (±7.78)           | 0.113   |

*The skewed distributed variables were expressed as the median and interquartile range (25–75%) and the Mann–Whitney U test was used

+The normally distributed variables were described as the means ± standard deviation (SD), and two independent sample t-test was used. Comparisons of categorical variables between groups were conducted using the chi-square test
PCR results, further emphasizing the fact that getting negative molecular testing is not usually as reliable as a positive result is. Albeit molecular testing is the gold standard method of in vitro diagnostic, the often long-waiting time to receive results, as well as the alarming rate of false negatives (30–50%), is daunting challenges facing us [10]. Considering the fact that diagnostic limitations are even more underscored in countries with restricted resources further discloses the necessity to apply simple alternative methods to diagnose COVID-19 patients. According to the results of CBC tests applied for 1537 (99.4%) patients, decreased number of lymphocytes (observed in 31.4% cases) along with increased neutrophil count (displayed in 38.9% cases) are seemingly appropriate items that should be taken into account in the identification of COVID-19. In agreement, decreased number of lymphocytes was reported in studies conducted on 207 and 149 COVID-19 patients [11, 12]; however, and inconsistent with our results, they

| Table 3  | Values of laboratory parameters in COVID-19 patients |
|----------|------------------------------------------------------|
| **Inflammation-related** | **Normal ranges** | All patients (N = 1546) | PCR negative (N = 439) | PCR positive (N = 1011) | P value |
| **ESR** | Up to 20 | 42 (26–61) | 45 (26–69) | 41 (26–60) | 0.009 |
| > 20 | | 82.5% | 81.8% | 82.2% | 0.848 |
| **CRP** | Up to 5 | 21.55 (8.87–51.52) | 23.4 (7.8–60.7) | 21.2 (9.5–50.8) | 0.862 |
| > 5 | | 87.3% | 83.4% | 88.8% | 0.004 |

| **Biochemical** | **Normal ranges** | All patients (N = 1546) | PCR negative (N = 439) | PCR positive (N = 1011) | P value |
| **Cr** | 0.7–1.2 mg/dL | 1.10 (1.00–1.30) | 1.1 (1.0–1.3) | 1.1 (1.0–1.4) | 0.074 |
| > 1.2 | | 46.9% | 46% | 49.6% | 0.215 |
| **BUN** | 7–19 mg/dL | 14 (9–20) | 15 (9–20) | 14 (9–20) | 0.326 |
| > 19 | | 28% | 29.6% | 28.4% | 0.636 |
| **CPK** | Female: 26–140 U/L | 137 (83.5–274) | 141 (85–271.75) | 133 (80–268) | 0.381 |
| Male: 38–174 U/L | | 36% | 35.3% | 37.8% | 0.37 |
| <140 (Female) | | 36% | 35.3% | 37.8% | 0.37 |
| <175 (Male) | | 43% | 43.5% | 44.4% | 0.75 |
| **LDH** | 207–414 U/L | 618 (509–780.25) | 616 (512–759.5) | 624 (508.5–803.5) | 0.386 |
| >415 | | 74.8% | 72.7% | 76.9% | 0.088 |
| **AST** | 10–40 U/L | 35 (25–51) | 32.5 (24–49) | 36 (26–52) | 0.01 |
| >40 | | 33.4% | 30.1% | 35.2% | 0.057 |
| **ALT** | 10–45 U/L | 37 (22–64) | 35 (23–59) | 39 (23–66.25) | 0.232 |
| >45 | | 33.2% | 30.5% | 36.2% | 0.037 |

| **Electrolytes** | **Normal ranges** | All patients (N = 1546) | PCR negative (N = 439) | PCR positive (N = 1011) | P value |
| **Na** | 136 – 145 | 141.13 (±4.88) | 140.85 (±4.75) | 141.35 (±4.98) | 0.073 |
| **K** | 3.5 – 5.0 | 4.59 (±0.6) | 4.59 (±0.6) | 4.62 (±0.61) | 0.49 |

| **Blood gas-related** | **Normal ranges** | All patients (N = 1546) | PCR negative (N = 439) | PCR positive (N = 1011) | P value |
| **pH** | 7.35–7.45 | 7.42 (7.33–7.47) | 7.42 (7.33–7.47) | 7.41 (7.32–7.47) | 0.585 |
| <7.35 | | 7.8% | 7.7% | 8.4% | 0.908 |
| >7.45 | | 10.2% | 10.3% | 10.4% | |
| **PO2** | 75–100 | 46.37 (±19.16) | 46.04 (±18.21) | 46.59 (±79.59) | 0.8 |
| <50 | | 23.9% | 23.5% | 25.1% | 0.5 |
| **PCO2** | 35–45 | 49.65 (±15.87) | 49.08 (±15.33) | 50.41 (±16.13) | 0.46 |
| >45 | | 15.1% | 14.8% | 16.5% | 0.414 |
| **O2 Sat.** | >95 | 71.64 (±20.67) | 71.97 (±19.44) | 71.45 (±21.1) | 0.822 |
| <94 | | 23% | 22.8% | 24.3% | 0.524 |
| **HCO3–** | 22–26 | 25.45 (±6.55) | 25.35 (±5.35) | 25.6 (±7.03) | 0.7 |
| Lactate | 0.3–0.8 mmol | 1.8 (1.2–2.7) | 1.6 (1.05–2.6) | 1.9 (1.25–2.8) | 0.049 |

The skewed distributed variables were expressed as the median and interquartile range (25–75%) and the Mann–Whitney U test was used.

The normally distributed variables were described as the means ± standard deviation (SD), and two independent sample t-test was used. Comparisons of categorical variables between groups were conducted using the chi-square test.

PCR results, further emphasizing the fact that getting negative molecular testing is not usually as reliable as a positive result is. Albeit molecular testing is the gold standard method of in vitro diagnostic, the often long-waiting time to receive results, as well as the alarming rate of false negatives (30–50%), is daunting challenges facing us [10]. Considering the fact that diagnostic limitations are even more underscored in countries with restricted resources further discloses the necessity to apply simple alternative methods to diagnose COVID-19 patients. According to the results of CBC tests applied for 1537 (99.4%) patients, decreased number of lymphocytes (observed in 31.4% cases) along with increased neutrophil count (displayed in 38.9% cases) are seemingly appropriate items that should be taken into account in the identification of COVID-19. In agreement, decreased number of lymphocytes was reported in studies conducted on 207 and 149 COVID-19 patients [11, 12]; however, and inconsistent with our results, they


demonstrated that neutrophil count is lower in SARS-CoV-2 infection than normal counterparts. Decreased levels of hemoglobin and mild thrombocytopenia, which were present respectively in 40% and 18.6% of our cases, may probably work hand in hand with the altered number of lymphocytes and neutrophils, and will all work together to better identify COVID-19 patients. While no significant association was found between platelets and the disease in a study by Ferrari et al. [11], Cheng et al. [13] revealed a significant correlation between the low number of platelets and COVID-19. There are also several studies representing that decreased levels of hemoglobin and platelet may contribute to facilitating the diagnosis of patients with COVID-19 [14–16].

Given the fact that the primary site of the SARS-CoV-2 attack is the lower respiratory tracts together with knowing LDH as an important marker of lung damage [17] may explain, at least partly, the elevated levels of this enzyme in the majority of COVID-19 patients [15, 18, 19]. Consistently, we found that approximately 75% of 1258 COVID-19 cases who had an LDH result displayed an increased level of LDH with the median value of 618 U/L. Notwithstanding atypical pneumonia being the primary symptom, the emergence of severe disease mainly resulting from the injury of non-pulmonary organs may also explicate abnormal values of kidney- and liver-related biochemical parameters. Analysis of creatinine and BUN in 1540 cases revealed that 50% and 28% of COVID-19 patients display increased levels of the aforementioned factors, which may effectively contribute to mirror virus-mediated kidney impairment. In addition, elevations in the enzymatic levels of AST and ALT nearly in 33% of 1290 patients (who had AST and ALT results) may also reflect the deteriorating ability of SARS-CoV-2 in induction of liver injury. In a study conducted by Guan et al., it has been reported that ALT and AST levels of COVID-19 patients were elevated in 21.3% and 22.2% of cases, respectively [20]. Albeit ESR and CRP were elevated in 82% and 87% of COVID-19 cases in our study, non-specific alteration in the wide range of infectious conditions, thus including SARS-CoV-2 infection, may profoundly diminish the diagnostic value of these factors in discriminating between patients with or without COVID-19. Given this, even though they still retain specific diagnostic value, it is important to note that the increased amounts of these factors may be beneficial only when they are taking into account in combination with the aforementioned laboratory abnormalities. On the whole and to provide a well-organized viewpoint representing the importance of routine blood tests as a potential diagnostic tool for COVID-19, we summarized alteration rate of the indicated parameters which have been previously reported in several pertinent literature (Table 4).

Albeit the results of this study declared the potential diagnostic value of routine laboratory parameters in SARS-CoV-2 infection, several limitations may adversely affect our analysis. Actually, this study was a retrospective study and 96 cases had no PCR results. Moreover, all the listed parameters did not perform for all the studied cases. The absence of recorded patients’ clinical signs also denotes a major limitation to the current study; however, we hope that the results of our study will shed more light on the diagnostic significance of these parameters in COVID-19, as the latest biological hazard to assume a sinister worldwide threat.

| Table 4 Alteration rate of laboratory parameters in our study and several pertinent literatures |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Present Study | Chen et al. | Yang et al. | Liu et al. | Cao et al. | Chen et al. | Guan et al. | Wan et al. | Xu et al. |
| CBC | | | | | | | | |
| Lymphocytes | ↓31.4% | ↓35% | ↓35.5% | ↓55% | ↓8.9% | ↓69% | ↓83.2% | ↓50% | ↓42% |
| Neutrophils | ↑38.9% | ↑38% | ↑4% | ↑17% | ↑6.2% | | | | |
| Platelets | ↓18.6% | ↓12% | ↓13.4% | ↓8% | ↓17.6% | ↓17% | ↓36.2% | ↓17% | ↓5% |
| Inflammation | | | | | | | | |
| CRP | ↑87.3% | ↑86% | ↑55% | ↑83% | ↑78.4% | ↑93% | ↑60.7% | | |
| ESR | ↑82.5% | ↑85% | | | ↑86.8% | | | | |
| Biochemical | | | | | | | | |
| Cr | ↑46.9% | ↑3% | ↑28.8% | ↑17% | ↑15.3% | ↑17% | ↑4.4% | ↑5% | |
| LDH | ↑74.8% | ↑76% | ↑30% | ↑92% | ↑69% | ↑41% | ↑43% | ↑127% | |
| ALT | ↑33.2% | ↑28% | ↑12% | ↑17% | ↑10.8% | ↑17% | ↑21.3% | | |
| AST | ↑33.4% | ↑35% | ↑18% | ↑18% | ↑17.4% | ↑24% | ↑22.2% | ↑22% | ↑16% |
References

1. World Health Organization (2020) Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
2. O’Shea PM, Lee GR, Griffin TP, Tormey V, Hayat A, Costelloe SJ et al (2020) COVID-19 in adults: test menu for hospital blood science laboratories. Ir J Med Sci (1971-) 189:1147–1152
3. Lu H, Stratton CW, Tang YW (2020) The Wuhan SARS-CoV-2—what’s next for China. J Med Virol 92(6):546–547
4. Bashash D, Abolghasemi H, Naseri P, Cheraghali AM, Soltanpoor MJ, Fooladi AA (2021) The association of age sex and RT-PCR results with the lymphocyte and neutrophil counts in SARS-CoV-2 infection: a cross-sectional analysis of 1450 Iranian patients with COVID-19. Iran J Allergy Asthma Immunol 1–11
5. Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed Atenei Parmensis 91(1):157–160
6. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 20(7):773
7. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J (2020) Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 296(2):E41–E45
8. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W et al (2020) Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 296(2):E32–E40
9. Tahamtan A, Ardebili A (2020) Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 20(5):453–454
10. Xiao AT, Tong YX, Zhang S (2020) False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. J Med Virol
11. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M (2020) Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med 58(7):1095–1099
12. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A et al (2020) Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang. China J Infect 80(4):388–393
13. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F et al (2020) Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai China. Am J Roentgenol 215(1):121–126
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan China: a descriptive study. Lancet 395(10223):507–513
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan China: a retrospective cohort study. Lancet 395(10229):1054–1062
16. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J et al (2020) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis 43:E005–E005
17. Jurisic V, Radenkovic S, Konjevic G (2015) The actual role of LDH as tumor marker biochemical and clinical aspects. In: Scatena R (ed) Advances in Cancer Biomarkers. Springer, Dordrecht, pp 115–124
18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395(10223):497–506
19. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J et al (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 63(3):364–374
20. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720
21. Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y et al (2020) Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai China. medRxiv
22. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y et al (2020) Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 92(7):797–806
23. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L et al (2020) Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan China: retrospective case series. BMJ 368

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.